Nama's AI scorecard currently rates Adaptive Biotechnologies Sell (3.0 out of 10), a call computed from its profitability, cash generation, growth, valuation and balance sheet. It is a research reading, not investment advice.

When does ADPT report earnings?

Adaptive Biotechnologies's next scheduled report is on Feb 4, 2027. Analysts expect EPS of -$0.06.

What is the ADPT price target?

The median analyst price target from 7 analysts is $32.00, with a range of $21.00 – $35.00.

Is ADPT Shariah compliant?

Nama's AAOIFI-style screen reads Adaptive Biotechnologies as Shariah Compliant. Passes our debt, cash and income screen; not a scholar's ruling.

Nama Insights

Adaptive Biotechnologies (ADPT)

Healthcare · Diagnostics Research · NASDAQ

Adaptive Biotechnologies (ADPT) is a Healthcare company in the Diagnostics Research industry. It has a market capitalization of $4.53B and a free-cash-flow yield of -1.1%. Over the most recent reported fiscal year, revenue grew 54.8%. Nama's AI scorecard rates it Sell, 3.0 out of 10. On 12-month momentum it ranks in the leading band of its market.

AI scorecard

Sell · 3.0/10

Negative, at the mild end of Sell. As of Nov 7, 2026.

Momentum

Leading · +68.9% over 12 months ex. last

Top 20% of its market on the past year's steady rise.

Shariah screen

Shariah Compliant

Passes our debt, cash and income screen; not a scholar's ruling.

Off its high

-25.5%

How far the last close sits under the highest price of the past five years.

Market cap	$4.53B
Trailing P/E	—
Price / book	31.1
Price / sales	14.5
FCF yield	-1.1%
Dividend yield	—
Gross margin	75.6%
Operating margin	-12.2%
Net margin	-20.7%
Revenue growth (YoY)	+54.8%
Revenue growth (3-yr annual)	+14.3%
EPS growth (YoY)	—
FCF/share growth (YoY)	—
Beta	2.1
Exchange	NASDAQ
Sector	Healthcare
Industry	Diagnostics Research

ADPT earnings

Next report: Feb 4, 2027 (Q4 2026, EPS estimate -$0.06). Beat the EPS estimate in 3 of 4 recent quarters.

Quarter	Reported	EPS	Estimate	Surprise	Revenue
Q3 2026	Nov 4, 2026	$0.02	-$0.10	+120.0%	$83.90M
Q2 2026	Jul 29, 2026	-$0.25	-$0.13	-92.3%	$71.55M
Q1 2026	May 5, 2026	-$0.13	-$0.16	+18.8%	$70.87M
Q4 2025	Feb 5, 2026	-$0.09	-$0.18	+50.0%	$71.68M

ADPT analyst price target

Median target $32.00 from 7 analysts, ranging $21.00 – $35.00.

Diagnostics Research peers

Ticker	Company	Market cap	P/E
TMO	Thermo Fisher Scientific	$257.42B	28.1
DHR	Danaher	$161.86B	27.6
IDXX	IDEXX Laboratories	$53.26B	45.6
A	Agilent Technologies	$49.28B	28.8
WAT	Waters	$44.93B	31.8
IQV	IQVIA	$44.80B	21.2
NTRA	Natera	$44.78B	—
MTD	Mettler-Toledo International	$34.51B	37.2

Explore live ADPT data on Nama Insights →

ADPT FAQ

Is ADPT a buy?: Nama's AI scorecard currently rates Adaptive Biotechnologies Sell (3.0 out of 10), a call computed from its profitability, cash generation, growth, valuation and balance sheet. It is a research reading, not investment advice.
When does ADPT report earnings?: Adaptive Biotechnologies's next scheduled report is on Feb 4, 2027. Analysts expect EPS of -$0.06.
What is the ADPT price target?: The median analyst price target from 7 analysts is $32.00, with a range of $21.00 – $35.00.
Is ADPT Shariah compliant?: Nama's AAOIFI-style screen reads Adaptive Biotechnologies as Shariah Compliant. Passes our debt, cash and income screen; not a scholar's ruling.